MedTrace Logo

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

NCT02500914 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-10-05

No results posted yet for this study

Summary

This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.

The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.

Conditions

Interventions

DRUG

SC-002

SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks

Sponsors & Collaborators

  • Stemcentrx

    lead INDUSTRY

Principal Investigators

  • Julia Lawrence, D.O. · Novella Clinical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-08-23
Completion
2018-08-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500914 on ClinicalTrials.gov